false
0001855485
0001855485
2024-03-08
2024-03-08
0001855485
CLDI:CommonStockParValue0.0001PerShareMember
2024-03-08
2024-03-08
0001855485
CLDI:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember
2024-03-08
2024-03-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 8, 2024
Calidi
Biotherapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-40789 |
|
86-2967193 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
4475
Executive Dr., Suite 200,
San
Diego, CA |
|
92121 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (858) 794-9600
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
|
|
|
|
|
Common
stock, par value $0.0001 per share |
|
CLDI |
|
NYSE
American LLC |
|
|
|
|
|
Redeemable
warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per share |
|
CLDIWS |
|
NYSE
American LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
1.01 Entry into a Material Definitive Agreement.
On
March 8, 2024, Calidi Biotherapeutics, Inc. (the “Company,” “we” or “our”) entered into a settlement
agreement (the “Settlement Agreement”) with an investor who previously entered into a series of related agreements including
(i) an agreement with Calidi Cure, LLC, an affiliate of the Company, in connection with an equity financing to fund the purchase of Series
B Convertible Preferred Stock of Calidi Biotherapeutics (Nevada), Inc. (formerly Calidi Biotherapeutics, Inc.), a Nevada corporation
and our wholly-owned subsidiary (“Calidi”); (ii) a Non-Redemption Agreement with the Company; (iii) an OTC Equity Prepaid
Forward Purchase Agreement with the Company; and (iv) a Subscription Agreement with the Company (items (i) through (iv) collectively
“the Supplemental Funding Agreements”) for the purpose of satisfying the “Minimum Cash Condition” required under
the Business Combination agreement between First Light Acquisition Group, Inc., and Calidi, among others, which was consummated on September
12, 2023.
Pursuant
to the Settlement Agreement, (i) the investor purchased a $2.0 million convertible note from the Company for cash and (ii) the Company
issued to the investor a $1.5 million convertible note in consideration for the settlement of all claims related to the Supplemental
Funding Agreements. The $2.0 million convertible note and $1.5 million convertible note are collectively herein referred to as the “Convertible
Notes”. The Settlement Agreement also includes a mutual release of all claims by both parties.
The
Convertible Notes bear semiannual interest at 10.0% per annum and each mature on March 8, 2028, unless due earlier due to an event of
a default. After the earlier of 180 days or the effective date of a registration statement registering the Company’s common stock
underlying the Convertible Notes, the Company may prepay the Convertible Notes, including any interest earned thereon, without penalty.
The Convertible Notes also provide the investor a right to convert in whole or in part, the Principal Amount (as defined in the Convertible
Notes) and accrued interest into shares of our common stock at an initial note conversion price equal to 94% of the 10-day VWAP ending
the business day preceding execution of the Convertible Notes subject to a reset note conversion price equal to 94% of 10-day VWAP ending
on the thirtieth (30th) day after the effective date of the registration statement registering the common stock underlying the Convertible
Notes. In the event the Company completes a financing (i) of at least $8 million in an offering registered with the Securities and Exchange
Commission (the “SEC”); or (ii) of at least $2 million with a non-affiliated purchaser at an effective price of at least
150% of the initial note conversion price, then the Convertible Notes will be subject to mandatory conversion at the lower of the initial
note conversion price and reset note conversion price.
On
March 11, 2024, the Company entered into an amendment to the $1.5 million convertible note (the "Note Amendment"), which amended
Section 1(c) pertaining to conditions to closing, by deleting Section 1(c)(iii) in its entirety, which previously provided that the Principal
Amount be wired to the Company’s bank account. As disclosed above, the $1.5 million convertible note was issued by the Company
to the investor in consideration for the settlement of all claims related to the Supplemental Funding Agreements.
The
foregoing description of the Settlement Agreement, the Convertible
Notes and Note Amendment do
not purport to be complete and is qualified in their entirety by reference to the full text of the Settlement Agreement, the Convertible
Notes and the Note Amendment, which
are attached hereto as Exhibits 10.1, 10.2, 10.3 and
10.4 respectively,
and incorporated herein by reference.
Item
1.02 Termination of a Material Definitive Agreement.
Pursuant
to the terms of the Settlement Agreement as described in Item 1.01, which is incorporated herein by reference, upon the execution of
the Settlement Agreement, all outstanding obligations of the Supplemental Funding Agreements were terminated.
Item
2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The
information included in Item 1.01 of this Current Report is incorporated by reference into this Item 2.03.
Item
3.02 Unregistered Sales of Equity Securities
The
information set forth under Item 1.01 in this Form 8-K is incorporated herein by reference.
The
issuance of the Convertible Notes and the shares of common stock that may be issuable upon conversion of the Convertible Notes (the “Securities”)
were made to an accredited investor in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act,
as amended (the “Securities Act”) as provided in Rule 506(b) of Regulation D promulgated thereunder. The offering of the
Securities was not conducted in connection with a public offering, and no public solicitation nor advertisement was made or relied upon
by the investor in connection with the offering.
Item
9.01 Financial Statements and Exhibits.
†
Certain information contained in this exhibit has been omitted because it is both (i) not material and (ii) is the type that the Company
treats as private or confidential.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Calidi
Biotherapeutics, Inc. |
Dated:
March 12, 2024 |
|
|
|
By: |
/s/
Wendy Pizarro |
|
Name: |
Wendy
Pizarro |
|
Title: |
Chief
Legal Officer |
Exhibit
10.1
CERTAIN
IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS
AS PRIVATE OR CONFIDENTIAL. [*****] INDICATES THAT INFORMATION HAS BEEN REDACTED OR OMITTED.
Execution
Copy – 03/08/2024
SETTLEMENT
AGREEMENT AND RELEASE OF ALL CLAIMS
This
Settlement Agreement and Release of All Claims (the “Settlement Agreement”) is made by and between [*****] (collectively,
“[*****]” or the “[*****]”), on the one hand, and Calidi Biotherapeutics, Inc., a Delaware corporation,
formerly First Light Acquisition Group, Inc. (“FLAG,” a Special Purpose Acquisition Company (“SPAC”), and together
with Calidi Biotherapeutics, Inc., “Calidi”), Calidi Cure, LLC, a Delaware limited liability company and an affiliate of
Calidi (“Calidi Cure”) and Allan Camaisa, an individual (erroneously described as Seller Representative in the OTC Equity
Prepaid Forward Purchase Agreement referenced below and an affiliate of Calidi (“Camaisa”) on the other hand (Calidi, Calidi
Cure, and Camaisa collectively the “Calidi Party”) (the [*****] and the Calidi Party are referred to collectively
herein as the “Parties” and individually as a “Party”). This Settlement Agreement is intended to resolve any
and all disputes between the Parties and their affiliates as set forth below and extinguish those obligations described below.
RECITALS
WHEREAS,
on or about August 29, 2023, [*****] simultaneously entered into and executed related agreements including (i) an agreement with
Calidi Cure to fund the purchase of Calidi Series B Preferred Stock; (ii) a Non-Redemption Agreement with FLAG; (iii) an OTC Equity Prepaid
Forward Purchase Agreement with Calidi, FLAG, and Camaisa (“Confirmation”); and (iv) a Subscription Agreement with FLAG (items
(i) through (iv) of this preamble sentence collectively “the Supplemental Funding Agreements”) for the purposes of helping
FLAG to satisfy the “Minimum Cash Condition” requirement of Article 6.1(g) of the Agreement and Plan of Merger (the “Merger
Agreement” or “Business Combination Agreement”) between FLAG, Calidi Biotherapeutics, Inc., a Nevada corporation (the
“Target), and several or their subsidiaries and related parties, entered into on January 9, 2023, as amended;
WHEREAS,
the Parties disagree, and have voiced disagreement as set forth in various correspondence by the Parties and their counsel, regarding
the meaning, interpretation, effect, and/or enforceability of certain terms and conditions in the Supplemental Funding Agreements, including,
without limitation: (i) the meaning of “Recycled Shares,” “Backstop Investor Shares,” and “Share Consideration
Shares” in the Supplemental Funding Agreements; (ii) whether [*****] “Pricing Date Notice” as defined in the
Confirmation correctly set forth the number of “Recycled Shares” and “Additional Shares”; (iii) whether Calidi
owes additional payment(s) to [*****] pursuant to the Supplemental Funding Agreements; and (iv) whether conditions precedent for
shares purchased by [*****] to be considered Recycled Shares, Backstop Investor Shares, and Share Consideration Shares existed,
were met, or were not met (the “Dispute”).
WHEREAS,
the Parties wish to resolve the Dispute in connection with the Supplemental Funding Agreements, including, without limitation, all issues
concerning whether payment is due and owing to any Party, and/or the amount, timing, consideration, of such payment;
WHEREAS,
on February 27, 2024, the Parties executed a Summary of Binding Terms Convertible Notes Financing, which set forth a binding and enforceable
agreement as to the material terms associated with a settlement of the Dispute, all of which is incorporated herein by reference and
memorialized pursuant to this Settlement Agreement; and;
WHEREAS,
the Parties agree that this Settlement Agreement and the terms and conditions contained herein, is a Full Release by the Parties of the
Supplemental Funding Agreements and other potential liabilities or obligation, as provided herein.
AGREEMENT
NOW,
THEREFORE, in consideration of the covenants and agreements contained in this Settlement Agreement, and the other valuable consideration
described herein, the sufficiency of which is hereby acknowledged by all Parties, the Parties agree as follows.
1.
[*****] Purchase of Two Million Dollar ($2,000,000) Convertible Note. Upon the execution of this Settlement Agreement,
[*****] will purchase from Calidi a Two Million Dollar ($2,000,000) convertible note in a form identical to in Exhibit A hereto.
Upon the execution of this Settlement Agreement, [*****] will wire $2,000,000 to Calidi.
2.
Issuance of One Million Five Hundred Thousand Dollar ($1,500,000) Convertible Note. Upon the execution of this Settlement Agreement,
Calidi will issue to [*****] a One Million, Five Hundred Thousand Dollar ($1,500,000) convertible note in a form identical to
Exhibit B hereto.
3.
Termination of Outstanding Obligations Under the Supplemental Funding Agreements. Upon the execution of this Settlement Agreement,
all outstanding obligations of the Supplemental Funding Agreements will terminate.
4.
Reasonable Assistance of [*****] in Third Party Claims. [*****] agrees to use reasonable efforts to cooperate with
Calidi in any claim brought by Calidi against third parties to this Settlement Agreement related to the Supplemental Funding Agreements.
5.
Attorney Fees. Parties agree to bear their own attorney fees and legal costs in connection with this Settlement Agreement. However,
after closing of the respective convertible notes described in Section 1 and Section 2 herein, Calidi will pay [*****] up to $15,000
as reimbursement for reasonable and documented attorney’s fees incurred in connection with the structuring of the convertible notes.
Furthermore, upon prior written consent, which shall not be unreasonably withheld, Calidi agrees to pay [*****] attorney fees
and legal costs related to [*****] reasonable efforts to cooperate in any of Calidi’s claims against third parties.
6.
Mutual Release of all Claims.
a.
Release by [*****]. [*****], on behalf of itself, its predecessors, successors, direct and indirect parent
companies, direct and indirect subsidiary companies, companies under common control with any of the foregoing, affiliates, and assigns,
and its and their past, present, and future officers, directors, shareholders, interest holders, members, partners, attorneys retained
in connection with the Dispute, agents, employees, managers, representatives, assigns, and successors in interest, and all persons acting
by, through, under, or in concert with them, and each of them, hereby releases and forever discharges Calidi Party, together with its
predecessors, successors, direct and indirect parent companies, direct and indirect subsidiary companies, companies under common control
with any of the foregoing, affiliates, and assigns, and its and their past, present, and future officers, directors, shareholders, interest
holders, members, partners, attorneys retained in connection with the Dispute, agents, employees, managers, representatives, assigns,
and successors in interest, and all persons acting by, through, under or in concert with them (“[*****] Releasees”),
and each of them, from all known and unknown charges, complaints, claims, grievances, liabilities, obligations, promises, agreements,
controversies, damages, actions, causes of action, suits, rights, demands, costs, losses, debts, penalties, fees, wages, expenses (including
attorneys’ fees and costs actually incurred), and punitive damages, of any nature whatsoever, whether at law or in equity, or known
or unknown, which [*****] has, or may have had, against Calidi Party, whether or not apparent or yet to be discovered, or which
may hereafter develop, for any acts, claims, or omissions related to or arising from:
(i)
The Dispute; and/or
(ii)
The Supplemental Funding Agreements.
This
Settlement Agreement resolves any claim for relief that has or could have been alleged by [*****] against Calidi Party related
to or arising from the Dispute or the Supplemental Funding Agreements, no matter how characterized, including, without limitation, compensatory
damages, damages for breach of contract, bad faith damages, reliance damages, liquidated damages, punitive damages, costs, and attorneys’
fees. Nothing in this Settlement Agreement shall be construed as, or constitute, a release of any Party’s right to enforce the
terms of this Settlement Agreement.
[*****]
certifies that it has read the provisions of California
Civil Code Section 1542 and has consulted its own counsel regarding that section. [*****] waives any and all rights under California
Civil Code Section 1542, which states:
A
GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR
AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE
DEBTOR OR RELEASED PARTY.
[*****]
agrees and acknowledges that the released
claims extend to and include unknown and unsuspected claims.
[*****]
has made an investigation of the facts pertaining
to this Settlement Agreement and to the released claims as it deems necessary. [*****] is aware that it may hereafter discover
facts in addition to, contrary to, or different from those it now knows or believes to be true with respect to the matters set forth
herein. Nevertheless, it is the intention of [*****] to fully, finally, and forever settle and release all claims of any kind
or nature whatsoever that were in existence as of the date of this Settlement Agreement. In furtherance of the Parties’ intent,
the release in this Settlement Agreement shall remain in full and complete effect notwithstanding the discovery or existence of any additional,
contrary, or different facts.
b.
Release by Calidi Party. Calidi Party, on behalf of itself, its predecessors, successors, direct and indirect parent companies,
direct and indirect subsidiary companies, companies under common control with any of the foregoing, affiliates, and assigns, and its
and their past, present, and future officers, directors, shareholders, interest holders, members, partners, attorneys retained in connection
with the Dispute, agents, employees, managers, representatives, assigns, and successors in interest, and all persons acting by, through,
under, or in concert with them, and each of them, hereby releases and forever discharges [*****], together with its predecessors,
successors, direct and indirect parent companies, direct and indirect subsidiary companies, companies under common control with any of
the foregoing, affiliates, and assigns, and its and their past, present, and future officers, directors, shareholders, interest holders,
members, partners, attorneys retained in connection with the Dispute, agents, employees, managers, representatives, assigns, and successors
in interest, and all persons acting by, through, under or in concert with them (“Calidi Releasees”), and each of them, from
all known and unknown charges, complaints, claims, grievances, liabilities, obligations, promises, agreements, controversies, damages,
actions, causes of action, suits, rights, demands, costs, losses, debts, penalties, fees, wages, medical costs, pain and suffering, mental
anguish, emotional distress, expenses (including attorneys’ fees and costs actually incurred), and punitive damages, of any nature
whatsoever, whether at law or in equity, or known or unknown, which Calidi Party has, or may have had, against [*****], whether
or not apparent or yet to be discovered, or which may hereafter develop, for any acts, claims, or omissions related to or arising from:
(i)
The Dispute; and/or
(ii)
The Supplemental Funding Agreements.
This
Settlement Agreement resolves any claim for relief that has or could have been alleged by Calidi Party against [*****] related
to or arising from the Dispute or the Supplemental Funding Agreements, no matter how characterized, including, without limitation, compensatory
damages, damages for breach of contract, bad faith damages, reliance damages, liquidated damages, damages for humiliation and embarrassment,
punitive damages, costs, and attorneys’ fees. Nothing in this Settlement Agreement shall be construed as, or constitute, a release
of any Party’s right to enforce the terms of this Settlement Agreement.
Calidi
Party certifies that they have read the provisions of California Civil Code Section 1542 and has consulted their own counsel regarding
that section. Calidi Party waives any and all rights under California Civil Code Section 1542, which states:
A
GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR
AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE
DEBTOR OR RELEASED PARTY.
Calidi
Party agrees and acknowledges that the released claims extend to and include unknown and unsuspected claims.
Calidi
Party has made an investigation of the facts pertaining to this Settlement Agreement and to the released claims as they deem necessary.
Calidi Party is aware that they may hereafter discover facts in addition to, contrary to, or different from those they now know or believe
to be true with respect to the matters set forth herein. Nevertheless, it is the intention of Calidi Party to fully, finally, and forever
settle and release all claims of any kind or nature whatsoever that were in existence as of the date of this Settlement Agreement. In
furtherance of the Parties’ intent, the release in this Settlement Agreement shall remain in full and complete effect notwithstanding
the discovery or existence of any additional, contrary, or different facts.
7.
Other Actions. The Parties hereby agree that they have not filed any other complaints against any of the Parties in any state or
federal court; that they will not file any complaint arising out of or related to the Dispute or the Supplemental Funding Agreements
at any time hereafter other than as it relates to the enforcement of this Settlement Agreement; and that if such court assumes jurisdiction
of any such complaint against any of the Parties whenever filed other than the enforcement of this Settlement Agreement, they will request
such court to dismiss the matter with prejudice.
8.
No Admission of Liability. This Settlement Agreement and compliance with it shall not be construed as an admission by the Parties
of any liability whatsoever or as an admission by a Party of any wrongdoing including any violation of any rights under any common law,
statute, or contract. The Parties specifically disclaim any wrongdoing and disclaim any liability to each other for any violation of
their rights, including any violation of common law, statute, or contract.
9.
Representations and Warranties.
|
a. |
No Outstanding or Known
Future Claims or Causes of Actions. Each Party represents and warrants that it has not filed with any governmental agency or court
any type of action or report against the other Party, and currently knows of no existing act or omission by the other Party that may
constitute a claim or liability excluded from the released claims set out in Section 6, above. |
|
|
|
|
b. |
No Assignment of Claims. The Parties
expressly warrant that they have not transferred to any other person or entity any of the rights or causes of action released in this
Settlement Agreement. Each Party represents and warrants that they are the rightful owners of and have not encumbered, assigned, or
transferred, nor will they in the future attempt to encumber, assign, or transfer, any claim for relief or cause of action released
herein. |
|
c. |
Parties’ Authority to Settle.
Each Party represents and warrants that they has full authority to enter into, deliver, and perform under this Settlement Agreement,
and that all acts and actions have been taken to grant such authority, and that no third-party consent, which has not already been
obtained, is required. |
|
|
|
|
d. |
Signatories’ Authority to Execute
Settlement Agreement. Each signatory to this Settlement Agreement represents and warrants that they are authorized to execute
this Settlement Agreement on behalf of the Party for whom executed this Settlement Agreement. |
|
|
|
|
e. |
No Violation of By-laws, Covenants, or
Restrictions. Each Party warrants and represents that the Party’s execution of this Settlement Agreement, if an entity,
is not in violation of any By-law, Operating Agreement, Covenants, and/or other restrictions placed upon them by their respective
entities. |
|
|
|
|
f. |
No Reliance Upon Representations Other
Than Settlement Agreement. The Parties represent and acknowledge that in executing this Settlement Agreement they do not rely
and have not relied upon any representation or statement made by any other Party or by the agents, attorneys or representatives of
the other Party with regard to the subject matter of this Settlement Agreement, or its basis, or the effects of this Settlement Agreement
other than those representations specifically set forth in this written document. |
10.
No Waiver. The failure of any Party to insist upon strict adherence to any term of this Settlement Agreement on any occasion shall
not be deemed a waiver or deprive any Party of the right thereafter to insist upon strict adherence to that term or any other term of
this Settlement Agreement. Any waiver must be in a writing signed by the Party granting the waiver and must expressly state that it is
a waiver of such provision of this Settlement Agreement.
11.
Effect of Partial Invalidity. Should any part, term or provision of this Settlement Agreement be declared or determined by any
Court of competent jurisdiction to be wholly or partially illegal, invalid, or unenforceable, the legality, validity, and enforceability
of the remaining parts, terms or provisions of this Settlement Agreement shall not be affected thereby. Said illegal, invalid or unenforceable
part, term or provision shall be deemed not to be a part of this Settlement Agreement.
12.
Entire Agreement. This Settlement Agreement and the Summary of Binding Terms Convertible Notes Financing, dated February 27, 2024,
which is incorporated herein by reference, constitute the entire agreement between the Parties regarding settlement of the Dispute or
settlement of actual or potential claims arising out of or related to the Supplemental Funding Agreements. This Settlement Agreement
supersedes all prior agreements, written or oral, between or among the Parties regarding those the settlement of those claims, other
than the Summary of Binding Terms Convertible Notes Financing. No other agreement, statement, or promise made by one Party to another
as to any matter addressed in this Settlement Agreement shall be binding or valid. This Settlement Agreement cannot be orally modified.
Any amendment or modification to this Settlement Agreement must be in writing, signed by a duly authorized representative of each Party.
The Parties further represent that they are unaware of any agreement or promise, written or oral, between Calidi Releasees and/or anyone
else and [*****] Releasees and/or anyone else, that could serve as the basis for any claim or action against Calidi Releasees
or [*****] Releasees, respectively, that have not been released in this Settlement Agreement.
13.
Interpretation of Agreement. The Parties agree that any legal rule to the effect that ambiguities shall be resolved against the
drafting party shall not apply in any interpretation of this Settlement Agreement.
14.
Governing Law and Jurisdiction. This Settlement Agreement shall be interpreted in accordance with and governed by the internal
laws of the State of Delaware without giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction
other than the internal laws of the State of Delaware to the rights and duties of the parties. All disputes and controversies arising
out of or in connection with this Settlement Agreement shall be resolved exclusively by the state or federal courts located in New Castle
County in the State of Delaware, and each Party hereto agrees to submit to the jurisdiction of said courts and agrees that venue shall
lie exclusively with such courts.
15.
Counterparts. The Parties may execute this Settlement Agreement in counterparts which shall, in the aggregate, be signed by all
the Parties; and each counterpart shall be deemed an original instrument as against the party who has signed it.
16.
Voluntary and Knowing. This Settlement Agreement is executed voluntarily and without any duress or undue influence on the part
or behalf of the parties hereto.
17.
Confidentiality. The Parties represent and agree that they have and will keep the terms and amount of this Settlement Agreement
completely confidential, and that they will not hereafter disclose any information concerning this Settlement Agreement to anyone without
prior notice to the other Party; provided, however, that the Parties may make such disclosure to their immediate family, current and
prospective limited partners, and professional representatives (e.g., attorneys, custodians, accountants, auditors, tax preparers). If
any disclosures are made as provided in this paragraph, each individual shall first be informed of and agree to be bound by this confidentiality
clause, or other such disclosures required by law to enforce this Settlement Agreement. Notwithstanding the foregoing, in the event that
Calidi has been advised by its counsel that the terms of this Settlement Agreement must be disclosed in periodic filings with the Securities
and Exchange Commission (“SEC”) and filed as an exhibit to filings with the SEC, it may disclose the contents of this Settlement
Agreement and such Settlement Agreement, including any exhibits thereto with the SEC. In the event that Calidi discloses certain terms
and conditions of this Settlement Agreement in an SEC filing or as an exhibit to an SEC filing (“Publicly Disclosed Terms”)
and such Publicly Disclosed Terms are unredacted and become part of the public domain, then [*****] will no longer have any obligation
of Confidentiality related to the Publicly Disclosed Terms under this paragraph.
18.
Cooperation. Each Party agrees to take all actions and to make, deliver, sign, and file any other documents and instruments necessary
to carry out the terms, provisions, purpose, and intent of this Settlement Agreement.
I,
having read the foregoing Settlement Agreement and Release of All Claims and knowing the contents thereof, am effecting this Settlement
and executing this Release after having the opportunity to obtain legal advice from counsel, and I sign the same as my own free act.
|
Calidi
Biotherapeutics, Inc. |
|
|
Dated:
March 8, 2024 |
/s/
Allan Camaisa |
|
Allan
Camaisa, Chief Executive Officer |
|
Calidi
Cure, LLC |
|
|
|
/s/
Allan Camaisa |
Dated:
March 8, 2024 |
Allan Camaisa, Manager |
|
Allan
Camaisa, an Individual |
|
|
|
/s/
Allan Camaisa |
Dated:
March 8, 2024 |
Allan
Camaisa, an Individual |
|
[*****] |
|
|
|
/s/ [*****] |
Dated:
March 8, 2024 |
[*****],
General Partner |
|
[*****],
Managing Member |
Exhibit
A
Exhibit
B
Exhibit
10.2
CALIDI
BIOTHERAPEUTICS, INC.
CONVERTIBLE PROMISSORY NOTE
$2,000,000.00 |
San Diego, California |
|
March
8, 2024
|
FOR
VALUE RECEIVED, Calidi Biotherapeutics, Inc., a Delaware corporation (“Borrower”), hereby unconditionally promises
to pay to [__________], or its registered assigns____________ (“Holder”), in lawful money of the United
States of America in the principal amount of Two Million Dollars ($2,000,000.00) (“Principal Amount”) pursuant to
that certain Settlement Agreement and Release of All Claims dated March 8, 2024, by and among Borrower and Holder (the “Settlement
Agreement”), together with interest thereon in accordance with the terms hereof, from the date hereof until the date on which
this Convertible Promissory Note (the “Note”) is paid in full. “Closing” means the closing of the
issuance of the Note pursuant to Section 1(c) and the terms and conditions hereunder.
1.
Terms of Note.
(a)
Interest Rate. Interest on the then outstanding Principal Amount of this Note shall accrue semiannually at a rate per annum equal
to ten percent (10.0%), simple interest beginning on the date of this Note. All interest shall be calculated on the basis of the actual
daily balances of Principal Amount outstanding for the exact number of days elapsed, using a year of three hundred sixty-five (365) days.
All interest shall accrue and shall be payable on the Maturity Date in cash, or at the election of the Borrower, in-kind on the then
outstanding amount of the Obligations by increasing the principal amount of the Obligations by the amount of such scheduled interest
payment, or in-kind in Common Stock of the Borrower at the then-prevailing Note Conversion Price, provided the Borrower’s voting
common stock is traded on an established public trading market.
(b)
Maturity Date. Except as otherwise provided herein, the entire outstanding Principal Amount of this Note, together with all accrued
but unpaid interest payable thereon, shall be due and payable in full on the earlier of: (i) March 8, 2028 (the “Maturity Date”)
or (ii) an Event of Default (as defined below). Such payments shall be applied first to the payment of unpaid interest and second to
reduce the outstanding Principal amount.
(c)
Conditions to Closing. Upon satisfaction or waiver by the party sought to be benefited thereby of the conditions set forth in
this Section 1(c), the Closing shall occur. At Closing:
|
(i) |
the Note shall be duly executed
by the Borrower and Holder; |
|
(ii) |
the Settlement Agreement
shall be duly executed by the Borrower and Holder; and |
|
(iii) |
the Principal Amount shall be wired to Borrower’s
designated bank account. |
2.
Voluntary Prepayment. The unpaid Principal Amount, together with interest accrued thereon, may be prepaid by the Company, in whole
or in part, after the earlier of (i) 180 days from the issuance of this Note or (ii) the Effective Registration Date (as defined herein)
upon thirty (30) days’ prior written notice without penalty.
3.
Conversion. Holder shall have the right to convert, in whole or in part, the unpaid Principal Amount, together with accrued interest
thereon, of this Note into shares of Borrower’s Common Stock upon the earlier of (i) 180 days from the issuance of this Note or
(ii) the Effective Registration Date (as defined herein).
(a)
Voluntary Conversion. At Holder’s option, Holder may convert, in whole or in part, the Principal Amount and accrued interest
into a number of shares of Common Stock of the Company calculated by dividing (x) the Principal Amount and accrued interest to be converted
under the Note, by (y) the then-applicable Conversion Price, as the case may be, subject to adjustment, in any.
(b)
Mandatory Conversion. Provided that the Company completes a financing (the “Financing”) of its capital securities,
or securities that may be converted into or exercise into capital securities, (i) of at least $8 million, not including the Principal
Amount plus any accrued interest subject to the Mandatory Conversion, in an offering registered with the SEC; or (ii) of at least $2
million, not including the Principal Amount plus any accrued interest subject to the Mandatory Conversion, to non-affiliated purchaser(s)
at an effective price of at least 150% of the Initial Note Conversion Price, Holder will be required to convert all, but not less than
all (subject to the exchange limit set forth in paragraph 3(k) below), Principal Amount plus any accrued interest, into shares of Common
Stock at the lower of the then-applicable Conversion Price and the effective price of such Financing; provided, however, that such mandatory
conversion shall only be required if the Borrower if the Common Stock is then currently listed for trading on the NYSE or Nasdaq, and
either (i) a resale shelf registration statement is in effect at the time of delivery of Common Stock permitting the Holder to sell all
such shares of Common Stock to be received upon the Mandatory Conversion, (ii) the Holder thereof may sell all such shares under Rule
144 within a three-month period and such Holder, together with its affiliates, owns less than 1% of the outstanding shares of Common
Stock, or (iii) in the case of a public offering, the Holder receives the same registered securities in the public offering in exchange
for and in satisfaction of the unpaid Principal and accrued interest thereon.
|
(i) |
For a Mandatory Conversion
in connection with a registered public offering to be effective, the Borrower shall provide notice to Holder at least one (1) Business
Day prior to the pricing date. |
|
(ii) |
For a Mandatory Conversion in connection with an offering with an effective price of at least 150%
of the Initial Note Conversion Price, the Borrower shall provide notice of Mandatory Conversion not more than ten (10) Business Days
after the closing of the offering, selecting a Mandatory Conversion Date not less than ten (10) Business Days and not more than
twenty (20) Business Days after the date on which the Borrower provides the notice of Mandatory Conversion to the Holder. The notice
shall state, as appropriate: |
|
(1) |
the Mandatory Conversion Date selected by the Borrower;
and |
|
(2) |
the conversion rate in effect
on the Mandatory Conversion Date, the amount of the outstanding principal amount and accrued interest on the Mandatory Conversion Date
and the number of shares of Common Stock to be delivered to Holder. |
(c)
Effectiveness of Conversion. The Conversion shall be deemed to have been made immediately prior to the close of business on the
Conversion Date, and the Holder shall be treated for all purposes as the record holder of the shares of Common Stock issued in the Conversion
as of such date.
(d) Reservation
of Shares. The Borrower shall at all times reserve and keep available out of its authorized and unissued Common Stock, solely
for issuance upon the conversion of the Convertible Note, such number of shares of Common Stock as shall from time to time be
issuable upon the conversion of all amounts outstanding under the Convertible Notes then outstanding. Any shares of Common Stock
issued upon conversion of amounts outstanding under the Note shall be duly authorized, validly issued, fully paid and
non-assessable.
(f)
Mechanics of Conversion. As promptly as practicable after the conversion of this Note, this Note shall be cancelled, and the Borrower
will issue and deliver to the Holder a certificate or certificates or evidence a book entry representing the full number of shares of
Common Stock (and the issuance of such certificate or certificates shall be made without charge to the Holder for any issuance in respect
thereof or other cost incurred by the Borrower in connection with such conversion and the related issuance of shares). No fractional
shares of Common Stock or scrip representing a fraction of a shares of the Common Stock will be issued upon conversion, but the number
of such shares issuable shall be rounded up to the nearest whole share.
(g)
Adjustments. If the Borrower at any time subdivides (by any stock split, stock dividend, recapitalization or otherwise), its outstanding
shares of Common Stock into a greater number of shares, the then applicable Conversion Price in effect immediately prior to such subdivision
will be proportionately reduced, and if the Borrower at any time combines (by reverse stock split, recapitalization or otherwise) its
outstanding shares of Common Stock into a smaller number of shares, the Conversion Price in effect immediately prior to such combination
will be proportionately increased.
(h)
Documentation. As a condition of effecting such conversion under this Section 3, Borrower shall execute and delivery all necessary
documents, and the Company will take all necessary steps and seek all necessary approvals, including, but not limited to, approval by
the NYSE American, to effect such conversion.
(i) Limitation
on Beneficial Ownership. The Holder shall not have the right to convert any of the Note held by such Holder pursuant to the
terms and conditions of this Note and any such conversion shall be null and void and treated as if never made, to the extent that
after giving effect to such conversion, such Holder together with the other attribution parties collectively would beneficially own
in excess of 9.99% (the “Maximum Percentage”) of the shares of Common Stock outstanding immediately after giving
effect to such conversion. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned
by such Holder and the other attribution parties shall include the number of shares of Common Stock held by such Holder and all
other attribution parties plus the number of shares of Common Stock issuable upon conversion of the Note with respect to which the
determination of such sentence is being made, but shall exclude shares of Common Stock which would be issuable upon (A) conversion
of the remaining, nonconverted Note beneficially owned by such Holder or any of the other attribution parties and (B) exercise or
conversion of the unexercised or nonconverted portion of any other securities of the Borrower (including, without limitation, any
convertible notes, convertible preferred stock or warrants) beneficially owned by such Holder or any other attribution party subject
to a limitation on conversion or exercise analogous to the limitation contained in this Section. For purposes of this Section,
beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the
“1934 Act”). For purposes of determining the number of outstanding shares of Common Stock a Holder may acquire upon the
conversion of the Note without exceeding the Maximum Percentage, such Holder may rely on the number of outstanding shares of Common
Stock as reflected in (x) the Borrower’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current Report
on Form 8-K or other public filing with the SEC, as the case may be, (y) a more recent public announcement by the Borrower or (z)
any other written notice by the Borrower or the transfer agent, if any, setting forth the number of shares of Common Stock
outstanding (the “Reported Outstanding Share Number”). If the Borrower receives a Conversion Notice from a Holder
at a time when the actual number of outstanding shares of Common Stock is less than the Reported Outstanding Share Number, the
Borrower shall notify such Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that such
Conversion Notice would otherwise cause such Holder’s beneficial ownership, as determined pursuant to this Section, to exceed
the Maximum Percentage, such Holder must notify the Borrower of a reduced number of shares of Common Stock to be purchased pursuant
to such Conversion Notice. For any reason at any time, upon the written or oral request of any Holder, the Borrower shall within one
(1) Business Day confirm orally and in writing or by electronic mail to such Holder the number of shares of Common Stock then
outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Borrower, including this Note, by such Holder and any other attribution party since the date as of
which the Reported Outstanding Share Number was reported. In the event that the issuance of shares of Common Stock to a Holder upon
conversion of this Note results in such Holder and the other attribution parties being deemed to beneficially own, in the aggregate,
more than the Maximum Percentage of the number of outstanding shares of Common Stock (as determined under Section 13(d) of the 1934
Act), the number of shares so issued by which such Holder’s and the other attribution parties’ aggregate beneficial
ownership exceeds the Maximum Percentage (the “Excess Shares”) shall be deemed null and void and shall be
cancelled ab initio, and such Holder shall not have the power to vote or to transfer the Excess Shares. Upon delivery of a written
notice to the Borrower, any Holder may from time to time increase (with such increase not effective until the sixty-first
(61st) day after delivery of such notice) or decrease the Maximum Percentage of such Holder to any other percentage not
in excess of 19.99% as specified in such notice; provided that (i) any such increase in the Maximum Percentage will not be effective
until the sixty-first (61st) day after such notice is delivered to the Borrower and (ii) any such increase or decrease
will apply only to such Holder and the other attribution parties and not to any other Holder that is not an attribution party of
such Holder. For purposes of clarity, the shares of Common Stock issuable to a Holder pursuant to the terms of this Note in excess
of the Maximum Percentage shall not be deemed to be beneficially owned by such Holder for any purpose including for purposes of
Section 13(d) or Rule 16a-1(a)(1) of the 1934 Act. No prior inability to convert this Note pursuant to this Section shall have
any effect on the applicability of the provisions of this Section with respect to any subsequent determination of
convertibility. The provisions of this Section shall be construed and implemented in a manner otherwise than in strict
conformity with the terms of this Section to the extent necessary to correct this Section (or any portion thereof) which may be
defective or inconsistent with the intended beneficial ownership limitation contained in this Section or to make changes or
supplements necessary or desirable to properly give effect to such limitation. The limitation contained in this Section may not
be waived and shall apply to a successor holder of this Note.
(j)
As used in this Note, the following capitalized terms have the following meaning.
“Common
Stock” shall mean the voting common stock of the Borrower.
“Conversion
Price” shall mean the “Initial Conversion Price” or the “Reset Conversion Price,” whichever is in effect
at the time of conversion.
“Initial
Note Conversion Price” shall equal 94.0% of the 10-day VWAP ending the business day preceding execution of this
Note.
“Reset
Note Conversion Price” shall equal 94.0% of 10-day VWAP ending on the thirtieth (30th) day after the Effective Registration Date.
“VWAP”
shall mean, for any trading day, the daily volume weighted average price of the shares of Common Stock for such trading day on the NYSE
American LLC (or such other market or exchange on which the shares of Common Stock are then listed or traded) during regular trading
hours as reported by Bloomberg L.P.
(k) Compliance
with Rules of Principal Market. Notwithstanding anything to the contrary herein, Holder shall not convert the Principal Amount
and accrued interest under this Note (or any other note issued to Holder under the Settlement Agreement) if the aggregate number of
shares of Common Stock that is converted under this Note (and any other note issued to Holder under the Settlement Agreement) would
exceed 7,068,920 (representing 19.99% of the aggregate amount of Common Stock issued and outstanding as of the date of this
Agreement, such maximum number of shares, the “Exchange Cap”); provided, however, that the Exchange Cap will not apply
if the Company’s stockholders have approved the conversion into Common Stock in excess of the Exchange Cap in accordance with
the rules of the NYSE American or the rules of the then stock exchange on which the Holder’s shares of Common Stock are
listed. In connection with each conversion notice and subject to compliance with the rules of the NYSE American, any portion of a
conversion that would exceed the Exchange Cap shall automatically be withdrawn with no further action required by the Holder and
such conversion notice shall be deemed automatically modified to reduce the aggregate amount of the conversion requested so that
such aggregate of conversion of shares of Common Stock by Holder will be less than the Exchange Cap.
(l) Failure
to Deliver Common Stock Prior to Delivery Deadline. Without in any way limiting the Holder’s right to pursue other
remedies, including actual damages and/or equitable relief, the parties agree that if delivery of the Common Stock issuable upon
conversion of this Note is not delivered within three (3) Business Days of any conversion (the “Deadline”), the
Borrower shall pay to the Holder $2,000 per day in cash, for each day beyond the Deadline that the Borrower fails to deliver such
Common Stock until the Borrower issues and delivers a certificate to the Holder or provides evidence of such delivery and book entry
form to the Holder the number of shares of Common Stock to which the Holder is entitled upon such Holder’s conversion of any
Conversion Amount (under Holder’s and Borrower’s expectation that any damages will tack back to the Issue Date). Such
cash amount shall be paid to Holder by the fifth day of the month following the month in which it has accrued or, at the option
of the Holder (by written notice to the Borrower by the first day of the month following the month in which it has accrued), shall
be added to the principal amount of this Note, in which event interest shall accrue thereon in accordance with the terms of this
Note and such additional principal amount shall be convertible into Common Stock in accordance with the terms of this Note. The
Borrower agrees that the right to convert is a valuable right to the Holder. The damages resulting from a failure, attempt to
frustrate, interference with such conversion right are difficult if not impossible to qualify. Accordingly the parties acknowledge
that the liquidated damages provision contained herein are justified.
4.
Events of Default. Upon the occurrence of any of the following events (“Event of Default”), the Borrower shall be
in default hereunder.
(a)
failure by the Borrower to pay when due any of the principal or accrued and unpaid interest hereunder; and such default shall have continued
for a period of thirty days (30) days;
(b)
the Borrower (i) applies for or consents to the appointment of a receiver, trustee, custodian or liquidator of itself or any part of
its property, (ii) becomes subject to the appointment of a receiver, trustee, custodian or liquidator of itself or any part of its
property if such appointment is not terminated or dismissed within sixty (60) days, (iii) makes an assignment for the benefit of
creditors, (iv) is adjudicated as bankrupt or insolvent, (v) institutes any proceedings under the United States Bankruptcy Code or
any other federal or state bankruptcy, reorganization, receivership, insolvency or other similar law affecting the rights of
creditors generally, or files a petition or answer seeking reorganization or an arrangement with creditors to take advantage of any
insolvency law, or files an answer admitting the material allegations of a bankruptcy, reorganization or insolvency petition filed
against it, or (vi) becomes subject to any proceedings under the United States Bankruptcy Code or any other federal or state
bankruptcy, reorganization, receivership, insolvency or other similar law affecting the rights of creditors generally, which
proceeding is not dismissed within sixty (60) days of filing, or has an order for relief entered against it in any proceeding under
the United States Bankruptcy Code.
(c)
the Borrower’s Common Stock is no longer listed on the NYSE American or the Nasdaq Stock Market.
If
an Event of Default occurs, all indebtedness under this Note shall become immediately due and payable, and the Borrower shall
immediately pay to Holder all amounts outstanding hereunder. Upon the occurrence of any Event of Default and at any time thereafter
during the continuance of such Event of Default, Holder may, by written notice to the Borrower, declare all outstanding indebtedness
payable by the Borrower hereunder to be immediately due and payable without presentment, demand, protest or any other notice of any
kind, all of which are hereby expressly waived, anything contained herein to the contrary notwithstanding. Upon the occurrence of
any Event of Default, immediately and without notice, all outstanding indebtedness payable by the Borrower hereunder shall
automatically become immediately due and payable, without presentment, demand, protest or any other notice of any kind, all of which
are hereby expressly waived, anything contained herein to the contrary notwithstanding. In addition to the foregoing remedies, upon
the occurrence and during the continuance of any Event of Default, Holder may exercise any other right, power or remedy granted to
it by this Note or otherwise permitted to it by law, either by suit in equity or by action at law, or both.
5.
Registration Rights.
(a) Filing
of a Registration Statement. Upon a written demand by Holder, Borrower shall prepare and file with the Securities and Exchange
Commission (“SEC”) a Registration Statement for the resale by the Holder of the Common Stock issuable upon the
conversion of the Note (and shares of Common Stock issuable upon the conversion of another note issued in connection with the
Settlement Agreement) as soon as practicable after the effective date of the Settlement Agreement and Release of All Claims.
Notwithstanding the foregoing, Borrower will have the right to delay the filing of such Registration Statement if the Borrower
provides notice to Holder that it intends to effect a registered public offering of its securities by April 30, 2024. In the event
that Borrower gives notice to Holder that it intends to conduct a registered public offering, Borrower shall have the right to delay
the filing of a Registration Statement under this Section 5(a) until the lapse of any restrictive period prohibiting the filing of
registration statements required under the public offering. The Borrower shall use its best efforts to have such Registration
Statement declared effective by the SEC as soon as practicable. The effectiveness date of the Registration Statement under this
Section 5(a) or (b) shall be deemed the Effective Registration Date; provided, however, that if the Effective Registration Date
shall not have occurred prior to 180 days from the issuance of this Note, the Effective Registration Date as defined in this Note
shall be deemed to occur on the 181st day after the issuance of this Note.
(b) Piggyback
Registration. If the Registration Statement provided for in subsection (a) above has not been filed and declared effective by
the SEC, and if Borrower determines on or after ninety (90) days from the issuance of this Note to prepare and file with the SEC
a registration statement or offering statement relating to an offering for its own account or the account of others under the
Securities Act of 1933, as amended (“Securities Act”), of any of its equity securities (other than on Form S-4 or
Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity securities to be issued solely
in connection with any acquisition of any entity or business or equity securities issuable in connection with the
Company’s stock option or other employee benefit plans), then the Borrower shall deliver to the Holder a written notice of
such determination and, if within fifteen (15) days after the date of the delivery of such notice, such Holder shall so request
in writing, the Borrower shall include in such registration statement or offering statement all Common Stock that may be issued
in connection with the conversion of this Note such Holder requests to be registered; provided, however, the Company shall not
be required to register any shares of Common Stock pursuant to this Section 5(b) that are eligible for resale pursuant to Rule
144 without restriction (including, without limitation, volume restrictions) and without the need for current public information
required by Rule 144(c)(1) (or Rule 144(i)(2), if applicable) or that are the subject of a then-effective Registration
Statement.
(c)
Cutback. If an underwriter or placement agent that is to be engaged in an underwritten offering or best efforts offering advises
the Borrower in good faith that the dollar amount or number of Common Stock which the Holder desires to sell under this Section 5(a)
or (b), exceeds the maximum dollar amount or maximum number of shares that can be sold in such offering without adversely affecting the
proposed offering price, the timing, the distribution method, or the probability of success of such offering, then the Company, and its
underwriter or placement agent, will have to right to reduce the number of Common Stock requested to be registered by such Holder on
a pro rata basis.
(d)
Maintaining a Registration Statement. The Borrower shall maintain the effectiveness of any Registration Statement that has been
declared effective at all times, provided, however, that if the Borrower has received notification pursuant to Section 3(e) above that
the Holder has completed resales pursuant to the Registration Statement for all the shares of Common Stock, then the Borrower shall be
under no further obligation to maintain the effectiveness of the Registration Statement. Notwithstanding anything to the contrary contained
in this Note, the Borrower shall ensure that, when filed, each Registration Statement (including, without limitation, all amendments
and supplements thereto) and the prospectus (including, without limitation, all amendments and supplements thereto) used in connection
with such Registration Statement shall not contain any untrue statement of a material fact or omit to state a material fact required
to be stated therein, or necessary to make the statements therein (in the case of prospectuses, in the light of the circumstances in
which they were made) not misleading. The Borrower shall notify the Holder promptly if (i) the Registration Statement shall cease to
be effective under the Securities Act, (ii) the Common Stock shall cease to be authorized for listing on the NYSE American, (iii) the
Common Stock ceases to be registered under Section 12(b) or Section 12(g) of the Exchange Act or (iv) the Borrower fails to
file in a timely manner all reports and other documents required of it as a reporting company under the Exchange Act.
(e)
Completion of Resale Pursuant to the Registration Statement. After the Holder has completed the subsequent resale of the shares
of Common Stock pursuant to the Registration Statement, Holder will notify the Company in writing (which may be by e-mail) that all subsequent
resales are completed and the Company will be under no further obligation to maintain the effectiveness of the Registration Statement.
(d) Filing
Procedures. The Borrower shall (A) permit counsel to the Holder an opportunity to review and comment upon (i) each Registration
Statement at least three (3) Trading Days prior to its filing with the SEC and (ii) all amendments and supplements to each
Registration Statement (including, without limitation, the prospectus contained therein) (except for Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any similar or successor reports or prospectus supplements the
contents of which is limited to that set forth in such reports) within a reasonable number of days prior to their filing with the
SEC, and (B) shall reasonably consider any comments of the Holder and its counsel on any such Registration Statement or amendment or
supplement thereto or to any prospectus contained therein. The Borrower shall promptly furnish to the Holder, without charge, (i)
electronic copies of any correspondence from the SEC or the staff to the Borrower or its representatives relating to each
Registration Statement (which correspondence shall be redacted to exclude any material, non-public information regarding the Company
or any of its subsidiaries), (ii) after the same is prepared and filed with the SEC, one (1) electronic copy of each Registration
Statement and any amendment(s) and supplement(s) thereto, including, without limitation, financial statements and schedules, all
documents incorporated therein by reference, if requested by the Holder, and all exhibits and (iii) upon the effectiveness of each
Registration Statement, one (1) electronic copy of the Prospectus included in such Registration Statement and all amendments and
supplements thereto; provided, however, the Company shall not be required to furnish any document to the extent such document is
available on EDGAR).
(e)
Amendments and Other Filings. The Borrower shall (i) prepare and file with the SEC such amendments (including post-effective amendments)
and supplements to a Registration Statement and the related prospectus used in connection with such Registration Statement, which prospectus
is to be filed pursuant to Rule 424 promulgated under the Securities Act, as may be necessary to keep such Registration Statement effective
at all times, and prepare and file with the SEC such additional Registration Statements in order to register for resale under the Securities
Act all of the Registrable Securities; (ii) cause the related prospectus to be amended or supplemented by any required prospectus supplement
(subject to the terms of this Note), and as so supplemented or amended to be filed pursuant to Rule 424 promulgated under the Securities
Act; (iii) provide the Holder copies of all correspondence from and to the SEC relating to a Registration Statement (provided that the
Company may excise any information contained therein which would constitute material non-public information, and (iv) comply with the
provisions of the Securities Act with respect to the Registration Statement. In the case of amendments and supplements to a Registration
Statement which are required to be filed pursuant to this Agreement (including pursuant to this Section 6.01(e) by reason of the Borrower’s
filing a report on Form 10-K, Form 10-Q, or Form 8-K or any analogous report under the Exchange Act, the Borrower shall file such
report in a prospectus supplement filed pursuant to Rule 424 promulgated under the Securities Act to incorporate such filing into the
Registration Statement, if applicable, or shall file such amendments or supplements with the SEC either on the day on which the Exchange
Act report is filed which created the requirement for the Borrower to amend or supplement the Registration Statement, if feasible, or
otherwise promptly thereafter.
6.
Representations and Warranties of the Borrower. The Borrower represents and warrants to the Holder that:
|
(a) |
Due Incorporation,
Qualification. The Borrower (i) is a corporation duly organized, validly existing and in good standing under the laws of the
State of Delaware; (ii) has the power and authority to own, lease and operate its properties and carry on its business as now
conducted; and (iii) is duly qualified, licensed to do business and in good standing as a foreign corporation in each jurisdiction
where the failure to be so qualified or licensed could reasonably be expected to have a material adverse effect on the
Borrower. |
|
(b) |
Authority. The execution, delivery and
performance by the Borrower of the Note and the consummation of the transactions contemplated thereby (i) are within the power of the
Borrower and (ii) have been duly authorized by all necessary actions on the part of the Borrower. |
|
(c) |
Enforceability. Each Note executed, or to be
executed, by the Borrower has been, or will be, duly executed and delivered by the Borrower and constitutes, or will constitute, a legal,
valid and binding obligation of the Borrower, enforceable against the Borrower in accordance with its terms, except as limited by bankruptcy,
insolvency or other laws of general application relating to or affecting the enforcement of creditors’ rights generally and general
principles of equity. |
|
(d) |
Non-Contravention. The execution and delivery
by the Borrower of the Note executed by the Borrower and the performance and consummation of the transactions contemplated thereby do
not and will not (i) violate the Charter or bylaws of the Borrower, or any material judgment, order, writ, decree, statute, rule or regulation
applicable to the Borrower; or (ii) result in the creation or imposition of any lien upon any property, asset or revenue of the Borrower
or the suspension, revocation, impairment, forfeiture, or nonrenewal of any material permit, license, authorization or approval applicable
to the Borrower, its business or operations, or any of its assets or properties. |
|
(e) |
Approvals. No consent, approval, order or authorization
of, or registration, declaration or filing with, any governmental authority or other person (including, without limitation, the shareholders
of any person) is required in connection with the execution and delivery of the Note by the Borrower and the performance and consummation
of the transactions contemplated thereby, other than such as have been obtained and remain in full force and effect and other than such
qualifications or filings under applicable securities laws as may be required in connection with the transactions contemplated by this
Note. |
|
(f) |
Shareholder Approval. In the event that the aggregate
number of shares of Common Stock that are convertible under this Note (and any other note issued to Holder under the Settlement Agreement)
would exceed the Exchange Cap, the Borrower shall cause a resolution seeking approval of the excess to be submitted for approval of the
stockholders at the next annual or special meeting, and any subsequent meeting until such approval is obtained. |
7.
Representations and Warranties of Holder. Holder represents and warrants to the Borrower upon the acquisition of the Note as follows:
|
(a) |
Binding Obligation. Holder has full legal
capacity, power and authority to execute and deliver this Note and to perform its obligations hereunder. This Note constitutes valid
and binding obligations of Holder, enforceable in accordance with its terms, except as limited by bankruptcy, insolvency or other laws
of general application relating to or affecting the enforcement of creditors’ rights generally and general principles of equity. |
|
(b) |
Securities Law Compliance. Holder has been advised
that the Note and the underlying securities have not been registered under the Act or any state securities laws and, therefore, cannot
be resold unless it or they are registered under the Act and applicable state securities laws or unless an exemption from such registration
requirements is available. Investor is aware that the Borrower is under no obligation to effect any such registration with respect to
the Note or the underlying securities or to file for or comply with any exemption from registration. Holder has not been formed solely
for the purpose of making this investment and is purchasing the Note for its own account for investment, not as a nominee or agent, and
not with a view to, or for resale in connection with, the distribution thereof, and Holder has no present intention of selling, granting
any participation in, or otherwise distributing the same. Holder has such knowledge and experience in financial and business matters
that Holder is capable of evaluating the merits and risks of such investment, is able to incur a complete loss of such investment without
impairing Holder’s financial condition and is able to bear the economic risk of such investment for an indefinite period of time.
Investor is an “accredited investor” as such term is defined in Rule 501 of Regulation D under the Act and shall submit to
the Borrower such further assurances of such status as may be reasonably requested by the Borrower. The residency of Holder (or, in the
case of a partnership or corporation, such entity’s principal place of business) is correctly set forth beneath Holder’s
name on the signature page hereto. |
|
(c) |
Access to Information. Holder acknowledges that
the Borrwer has given Holder access to the corporate records and accounts of the Borrower and to all information in its possession relating
to the Borrower, has made its officers and representatives available
for interview by Holder, and has furnished Holder with all documents and other information required for Holder to make an informed decision
with respect to the purchase of the Note. |
8. Amendment
and Waiver. Any provision of this Note may be amended, waived or modified only with the written consent of the Borrower and the
Holder provided however, that no such amendment, waiver or consent shall: (i) reduce the principal amount of any Note without
the Holder’s written consent, or (ii) reduce the rate of interest of any Note without the Holder’s written consent. Any
term of this Note may be amended and the observance of any term of this Note may be waived (either generally or in a particular
instance and either retroactively or prospectively), only with the written consent of the Borrower and Holder. Any amendment or
waiver effected in accordance with this paragraph shall be binding upon all of the parties hereto.
9. Assignment
by the Borrower. The rights, interests or obligations of the Borrower hereunder may not be assigned, by operation of law or
otherwise, in whole or in part, by the Borrower without the prior written consent of the Holder.
10.
Place of Payment. Payments of principal and interest and all notices and other communications to Holder hereunder or with respect
hereto are to be delivered to Holder such address as specified by Holder by prior written notice to the Borrower, including any transferee
of this Note.
11.
Costs of Collection. In the event that the Borrower fails to pay when due (including, without limitation upon acceleration in
connection with an Event of Default) the full amount of principal and/or interest hereunder, the Borrower shall indemnify and hold harmless
Holder of any portion of this Note from and against all costs and expenses incurred in connection with the enforcement of this provision
or collection of such principal and interest, including, without limitation, attorneys’ fees and expenses.
12. Waivers.
The Borrower hereby waives presentment, demand, notice, protest and all other demands and notices in connection with the delivery,
acceptance, performance, default or enforcement of this Note.
13. Mutilated,
Destroyed, Lost and Stolen Note. In case the Note shall be mutilated, lost, stolen or destroyed, the Borrower shall issue a new
Note of like date, tenor and denomination and deliver the same in exchange and substitution for and upon surrender and cancellation
of the mutilated Note, or in lieu of a lost, stolen or destroyed Note, upon receipt of evidence satisfactory to the Borrower of the
loss, theft or destruction of such Note.
14.
Interest Savings Clause. In the event any interest is paid on this Note which is deemed to be in excess of the then legal maximum
rate, then that portion of the interest payment representing an amount in excess of the then legal maximum rate shall be deemed a payment
of principal and applied against the principal of this Note.
15. Governing
Law. THIS NOTE AND THE RIGHTS AND DUTIES OF THE BORROWER AND HOLDER HEREOF SHALL BE GOVERNED BY, CONSTRUED IN AND ENFORCED
IN ACCORDANCE WITH, THE LAWS OF THE STATE OF DELAWARE TO CONTRACTS EXECUTED AND TO BE PERFORMED ENTIRELY WITHIN THAT STATE.
16.
Waiver of Jury Trial. The Borrower hereby agrees to waive their respective rights to a jury trial of any claim or cause of action
based upon or arising out of this Note.
17.
Jurisdiction. In the event of a dispute, Borrower and Holder agree to the jurisdiction set forth in the Settlement Agreement.
18. Survival
and Severability. The representations, warranties, covenants and agreements made herein shall survive the execution and delivery
of this Note. If any term, covenant or provision contained in this Note, or the application thereof to any Person or
circumstance, will be determined to be void, invalid, illegal or unenforceable to any extent or will otherwise operate to invalidate
this Note, in whole or part, then such term, covenant or provision only will be deemed not contained in this Note; the remainder of
this Note will remain operative and in full force and effect and will be enforced to the greatest extent permitted by law as if such
clause or provision had never been contained in it; and the application of such term, covenant or provision to other Persons or
circumstances will not be affected, impaired or restricted by that occurrence.
19. Entire
Agreement. This Note and the Settlement Agreement constitute, along with any exhibits hereto and thereto, and contain the entire
agreement among the Borrower and Holder and supersedes any and all prior agreements, negotiations, correspondence,
understandings and communications among the parties, whether written or oral, respecting the subject matter hereof.
20.
Notices. Any notice, request or other communication required or permitted hereunder will be in writing and be deemed to have been
duly given (a) when personally delivered or sent by email(the receipt of which is confirmed in writing); (b) one business day
after being sent by a nationally recognized overnight courier service; or (c) five business days after being sent by registered or
certified mail, return receipt requested, postage prepaid, to the parties at their respective addresses set forth below:
If
to the Borrower: Calidi Biotherapeutics, Inc.
4475
Executive Drive, Suite 200
San
Diego, CA 92121
wpizarro@calidibio.com
or contracts@calidibio.com
If
to the Holder: [__________]
IN
WITNESS WHEREOF, the Issuer has executed and delivered this Convertible Promissory Note on March 8, 2024
|
ISSUER: |
|
|
|
|
Calidi Biotherapeutics, Inc. |
|
|
|
|
By: |
|
|
Name: |
Allan
Camaisa |
|
Title: |
Chief
Executive Officer |
Acknowledged and Agreed: |
|
|
|
|
HOLDER: |
|
|
|
|
[__________] |
|
|
|
|
By: |
|
|
Name:
|
|
|
Title: |
|
|
Exhibit
10.3
CALIDI
BIOTHERAPEUTICS, INC.
CONVERTIBLE
PROMISSORY NOTE
$1,500,000.00 |
San Diego, California |
|
March
8, 2024
|
FOR
VALUE RECEIVED, Calidi Biotherapeutics, Inc., a Delaware corporation (“Issuer”), hereby unconditionally promises to
pay to [__________], or its registered assigns (“Holder”), in lawful money of the United States of America
in the principal amount of One Million Five Hundred Thousand Dollars ($1,500,000.00) (“Principal Amount”) pursuant
to that certain Settlement Agreement and Release of All Claims dated March 8, 2024, by and among Issuer and Holder (the “Settlement
Agreement”), together with interest thereon in accordance with the terms hereof, from the date hereof until the date on which
this Convertible Promissory Note (the “Note”) is paid in full. “Closing” means the closing of the
issuance of the Note pursuant to Section 1(c) and the terms and conditions hereunder.
1.
Terms of Note.
(a)
Interest Rate. Interest on the then outstanding Principal Amount of this Note shall accrue semiannually at a rate per annum equal
to ten percent (10.0%), simple interest beginning on the date of this Note. All interest shall be calculated on the basis of the actual
daily balances of Principal Amount outstanding for the exact number of days elapsed, using a year of three hundred sixty-five (365) days.
All interest shall accrue and shall be payable on the Maturity Date in cash, or at the election of the Issuer, in-kind on the then outstanding
amount of the Obligations by increasing the principal amount of the Obligations by the amount of such scheduled interest payment, or
in-kind in Common Stock of the Issuer at the then-prevailing Note Conversion Price, provided the Issuer’s voting common stock is
traded on an established public trading market.
(b)
Maturity Date. Except as otherwise provided herein, the entire outstanding Principal Amount of this Note, together with all accrued
but unpaid interest payable thereon, shall be due and payable in full on the earlier of: (i) March 8, 2028 (the “Maturity Date”)
or (ii) an Event of Default (as defined below). Such payments shall be applied first to the payment of unpaid interest and second to
reduce the outstanding Principal amount.
(c)
Conditions to Closing. Upon satisfaction or waiver by the party sought to be benefited thereby of the conditions set forth in
this Section 1(c), the Closing shall occur. At Closing:
|
(i) |
the Note shall be duly executed by the Issuer
and Holder; |
|
(ii) |
the Settlement Agreement shall be duly executed
by the Issuer and Holder; and |
|
(iii) |
the Principal Amount shall be wired to Issuer’s
designated bank account. |
2.
Voluntary Prepayment. The unpaid Principal Amount, together with interest accrued thereon, may be prepaid by the Company, in whole
or in part, after the earlier of (i) 180 days from the issuance of this Note or (ii) the Effective Registration Date (as defined herein)
upon thirty (30) days’ prior written notice without penalty.
3.
Conversion. Holder shall have the right to convert, in whole or in part, the unpaid Principal Amount, together with accrued interest
thereon, of this Note into shares of Issuer’s Common Stock upon the earlier of (i) 180 days from the issuance of this Note or (ii)
the Effective Registration Date (as defined herein).
(a)
Voluntary Conversion. At Holder’s option, Holder may convert, in whole or in part, the Principal Amount and accrued interest
into a number of shares of Common Stock of the Company calculated by dividing (x) the Principal Amount and accrued interest to be converted
under the Note, by (y) the then-applicable Conversion Price, as the case may be, subject to adjustment, in any.
(b)
Mandatory Conversion. Provided that the Company completes a financing (the “Financing”) of its capital securities,
or securities that may be converted into or exercise into capital securities, (i) of at least $8 million, not including the Principal
Amount plus any accrued interest subject to the Mandatory Conversion, in an offering registered with the SEC; or (ii) of at least $2
million, not including the Principal Amount plus any accrued interest subject to the Mandatory Conversion, to non-affiliated purchaser(s)
at an effective price of at least 150% of the Initial Note Conversion Price, Holder will be required to convert all, but not less than
all (subject to the exchange limit set forth in paragraph 3(k) below), Principal Amount plus any accrued interest, into shares of Common
Stock at the lower of the then-applicable Conversion Price and the effective price of such Financing; provided, however, that such mandatory
conversion shall only be required if the Issuer if the Common Stock is then currently listed for trading on the NYSE or Nasdaq, and either
(i) a resale shelf registration statement is in effect at the time of delivery of Common Stock permitting the Holder to sell all such
shares of Common Stock to be received upon the Mandatory Conversion, (ii) the Holder thereof may sell all such shares under Rule 144
within a three-month period and such Holder, together with its affiliates, owns less than 1% of the outstanding shares of Common Stock,
or (iii) in the case of a public offering, the Holder receives the same registered securities in the public offering in exchange for
and in satisfaction of the unpaid Principal and accrued interest thereon.
|
(i) |
For a Mandatory Conversion in connection with a registered public offering to be effective, the Issuer shall provide notice to Holder
at least one (1) Business Day prior to the pricing date. |
|
(ii) |
For a Mandatory Conversion in connection with an offering with an effective price of at least 150% of the Initial Note Conversion
Price, the Issuer shall provide notice of Mandatory Conversion not more than ten (10) Business Days after the closing of the offering,
selecting a Mandatory Conversion Date not less than ten (10) Business Days and not more than twenty (20) Business Days after the
date on which the Issuer provides the notice of Mandatory Conversion to the Holder. The notice shall state, as appropriate: |
|
(1) |
the Mandatory Conversion Date selected by the Issuer; and |
|
|
|
|
(2) |
the conversion rate in effect on the Mandatory Conversion
Date, the amount of the outstanding principal amount and accrued interest on the Mandatory Conversion Date and the number of shares of
Common Stock to be delivered to Holder. |
(c) Effectiveness
of Conversion. The Conversion shall be deemed to have been made immediately prior to the close of business on the Conversion Date,
and the Holder shall be treated for all purposes as the record holder of the shares of Common Stock issued in the Conversion as of such
date.
(d) Reservation of Shares. The Issuer shall at all times reserve and keep available out of its authorized and unissued Common Stock, solely for issuance upon the conversion of the Convertible Note, such number of shares of Common Stock as shall from time to time be issuable upon the conversion of all amounts outstanding under the Convertible Notes then outstanding. Any shares of Common Stock issued upon conversion of amounts outstanding under the Note shall be duly authorized, validly issued, fully paid and non-assessable.
(f) Mechanics of Conversion. As promptly as practicable after the conversion of this Note, this Note shall be cancelled, and the Issuer will issue and deliver to the Holder a certificate or certificates or evidence a book entry representing the full number of shares of Common Stock (and the issuance of such certificate or certificates shall be made without charge to the Holder for any issuance in respect thereof or other cost incurred by the Issuer in connection with such conversion and the related issuance of shares). No fractional shares of Common Stock or scrip representing a fraction of a shares of the Common Stock will be issued upon conversion, but the number of such shares issuable shall be rounded up to the nearest whole share.
(g)
Adjustments. If the Issuer at any time subdivides (by any stock split, stock dividend, recapitalization or otherwise), its outstanding
shares of Common Stock into a greater number of shares, the then applicable Conversion Price in effect immediately prior to such subdivision
will be proportionately reduced, and if the Issuer at any time combines (by reverse stock split, recapitalization or otherwise) its outstanding
shares of Common Stock into a smaller number of shares, the Conversion Price in effect immediately prior to such combination will be
proportionately increased.
(h)
Documentation. As a condition of effecting such conversion under this Section 3, Issuer shall execute and delivery all necessary
documents, and the Company will take all necessary steps and seek all necessary approvals, including, but not limited to, approval by
the NYSE American, to effect such conversion.
(i)
Limitation on Beneficial Ownership. The Holder shall not have the right to convert any of the Note held by such Holder pursuant
to the terms and conditions of this Note and any such conversion shall be null and void and treated as if never made, to the extent that
after giving effect to such conversion, such Holder together with the other attribution parties collectively would beneficially own in
excess of 9.99% (the “Maximum Percentage”) of the shares of Common Stock outstanding immediately after giving effect
to such conversion. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such
Holder and the other attribution parties shall include the number of shares of Common Stock held by such Holder and all other attribution
parties plus the number of shares of Common Stock issuable upon conversion of the Note with respect to which the determination of such
sentence is being made, but shall exclude shares of Common Stock which would be issuable upon (A) conversion of the remaining, nonconverted
Note beneficially owned by such Holder or any of the other attribution parties and (B) exercise or conversion of the unexercised or nonconverted
portion of any other securities of the Issuer (including, without limitation, any convertible notes, convertible preferred stock or warrants)
beneficially owned by such Holder or any other attribution party subject to a limitation on conversion or exercise analogous to the limitation
contained in this Section. For purposes of this Section, beneficial ownership shall be calculated in accordance with Section 13(d) of
the Securities Exchange Act of 1934, as amended (the “1934 Act”). For purposes of determining the number of outstanding shares
of Common Stock a Holder may acquire upon the conversion of the Note without exceeding the Maximum Percentage, such Holder may rely on
the number of outstanding shares of Common Stock as reflected in (x) the Issuer’s most recent Annual Report on Form 10-K, Quarterly
Report on Form 10-Q, Current Report on Form 8-K or other public filing with the SEC, as the case may be, (y) a more recent public announcement
by the Issuer or (z) any other written notice by the Issuer or the transfer agent, if any, setting forth the number of shares of Common
Stock outstanding (the “Reported Outstanding Share Number”). If the Issuer receives a Conversion Notice from a Holder
at a time when the actual number of outstanding shares of Common Stock is less than the Reported Outstanding Share Number, the Issuer
shall notify such Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that such Conversion
Notice would otherwise cause such Holder’s beneficial ownership, as determined pursuant to this Section, to exceed the Maximum
Percentage, such Holder must notify the Issuer of a reduced number of shares of Common Stock to be purchased pursuant to such Conversion
Notice. For any reason at any time, upon the written or oral request of any Holder, the Issuer shall within one (1) Business Day confirm
orally and in writing or by electronic mail to such Holder the number of shares of Common Stock then outstanding. In any case, the number
of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Issuer,
including this Note, by such Holder and any other attribution party since the date as of which the Reported Outstanding Share Number
was reported. In the event that the issuance of shares of Common Stock to a Holder upon conversion of this Note results in such Holder
and the other attribution parties being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number
of outstanding shares of Common Stock (as determined under Section 13(d) of the 1934 Act), the number of shares so issued by which such
Holder’s and the other attribution parties’ aggregate beneficial ownership exceeds the Maximum Percentage (the “Excess
Shares”) shall be deemed null and void and shall be cancelled ab initio, and such Holder shall not have the power to vote or
to transfer the Excess Shares. Upon delivery of a written notice to the Issuer, any Holder may from time to time increase (with such
increase not effective until the sixty-first (61st) day after delivery of such notice) or decrease the Maximum Percentage
of such Holder to any other percentage not in excess of 19.99% as specified in such notice; provided that (i) any such increase in the
Maximum Percentage will not be effective until the sixty-first (61st) day after such notice is delivered to the Issuer and
(ii) any such increase or decrease will apply only to such Holder and the other attribution parties and not to any other Holder that
is not an attribution party of such Holder. For purposes of clarity, the shares of Common Stock issuable to a Holder pursuant to the
terms of this Note in excess of the Maximum Percentage shall not be deemed to be beneficially owned by such Holder for any purpose including
for purposes of Section 13(d) or Rule 16a-1(a)(1) of the 1934 Act. No prior inability to convert this Note pursuant to this Section shall
have any effect on the applicability of the provisions of this Section with respect to any subsequent determination of convertibility.
The provisions of this Section shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this
Section to the extent necessary to correct this Section (or any portion thereof) which may be defective or inconsistent with the intended
beneficial ownership limitation contained in this Section or to make changes or supplements necessary or desirable to properly give effect
to such limitation. The limitation contained in this Section may not be waived and shall apply to a successor holder of this Note.
(j)
As used in this Note, the following capitalized terms have the following meaning.
“Common
Stock” shall mean the voting common stock of the Issuer.
“Conversion
Price” shall mean the “Initial Conversion Price” or the “Reset Conversion Price,” whichever is in effect
at the time of conversion.
“Initial
Note Conversion Price” shall equal 94.0% of the 10-day VWAP ending the business day preceding execution of this Note.
“Reset
Note Conversion Price” shall equal 94.0% of 10-day VWAP ending on the thirtieth (30th) day after the Effective Registration Date.
“VWAP”
shall mean, for any trading day, the daily volume weighted average price of the shares of Common Stock for such trading day on the NYSE
American LLC (or such other market or exchange on which the shares of Common Stock are then listed or traded) during regular trading
hours as reported by Bloomberg L.P.
(k)
Compliance with Rules of Principal Market. Notwithstanding anything to the contrary herein, Holder shall not convert the Principal
Amount and accrued interest under this Note (or any other note issued to Holder under the Settlement Agreement) if the aggregate number
of shares of Common Stock that is converted under this Note (and any other note issued to Holder under the Settlement Agreement) would
exceed 7,068,920 (representing 19.99% of the aggregate amount of Common Stock issued and outstanding as of the date of this Agreement,
such maximum number of shares, the “Exchange Cap”); provided, however, that the Exchange Cap will not apply if the Company’s
stockholders have approved the conversion into Common Stock in excess of the Exchange Cap in accordance with the rules of the NYSE American
or the rules of the then stock exchange on which the Holder’s shares of Common Stock are listed. In connection with each conversion
notice and subject to compliance with the rules of the NYSE American, any portion of a conversion that would exceed the Exchange Cap
shall automatically be withdrawn with no further action required by the Holder and such conversion notice shall be deemed automatically
modified to reduce the aggregate amount of the conversion requested so that such aggregate of conversion of shares of Common Stock by
Holder will be less than the Exchange Cap.
(l) Failure
to Deliver Common Stock Prior to Delivery Deadline. Without in any way limiting the Holder’s right to pursue other remedies,
including actual damages and/or equitable relief, the parties agree that if delivery of the Common Stock issuable upon conversion of
this Note is not delivered within three (3) Business Days of any conversion (the “Deadline”), the Issuer shall pay to the
Holder $2,000 per day in cash, for each day beyond the Deadline that the Issuer fails to deliver such Common Stock until the Issuer issues
and delivers a certificate to the Holder or provides evidence of such delivery and book entry form to the Holder the number of shares
of Common Stock to which the Holder is entitled upon such Holder’s conversion of any Conversion Amount (under Holder’s and
Issuer’s expectation that any damages will tack back to the Issue Date). Such cash amount shall be paid to Holder by the fifth
day of the month following the month in which it has accrued or, at the option of the Holder (by written notice to the Issuer by the
first day of the month following the month in which it has accrued), shall be added to the principal amount of this Note, in which event
interest shall accrue thereon in accordance with the terms of this Note and such additional principal amount shall be convertible into
Common Stock in accordance with the terms of this Note. The Issuer agrees that the right to convert is a valuable right to the Holder.
The damages resulting from a failure, attempt to frustrate, interference with such conversion right are difficult if not impossible to
qualify. Accordingly the parties acknowledge that the liquidated damages provision contained herein are justified.
4.
Events of Default. Upon the occurrence of any of the following events (“Event of Default”), the Issuer shall be in
default hereunder.
(a)
failure by the Issuer to pay when due any of the principal or accrued and unpaid interest hereunder; and such default shall have continued
for a period of thirty days (30) days;
(b)
the Issuer (i) applies for or consents to the appointment of a receiver, trustee, custodian or liquidator of itself or any part of its
property, (ii) becomes subject to the appointment of a receiver, trustee, custodian or liquidator of itself or any part of its property
if such appointment is not terminated or dismissed within sixty (60) days, (iii) makes an assignment for the benefit of creditors, (iv)
is adjudicated as bankrupt or insolvent, (v) institutes any proceedings under the United States Bankruptcy Code or any other federal
or state bankruptcy, reorganization, receivership, insolvency or other similar law affecting the rights of creditors generally, or files
a petition or answer seeking reorganization or an arrangement with creditors to take advantage of any insolvency law, or files an answer
admitting the material allegations of a bankruptcy, reorganization or insolvency petition filed against it, or (vi) becomes subject to
any proceedings under the United States Bankruptcy Code or any other federal or state bankruptcy, reorganization, receivership, insolvency
or other similar law affecting the rights of creditors generally, which proceeding is not dismissed within sixty (60) days of filing,
or has an order for relief entered against it in any proceeding under the United States Bankruptcy Code.
(c)
the Issuer’s Common Stock is no longer listed on the NYSE American or the Nasdaq Stock Market.
If
an Event of Default occurs, all indebtedness under this Note shall become immediately due and payable, and the Issuer shall immediately
pay to Holder all amounts outstanding hereunder. Upon the occurrence of any Event of Default and at any time thereafter during the continuance
of such Event of Default, Holder may, by written notice to the Issuer, declare all outstanding indebtedness payable by the Issuer hereunder
to be immediately due and payable without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly
waived, anything contained herein to the contrary notwithstanding. Upon the occurrence of any Event of Default, immediately and without
notice, all outstanding indebtedness payable by the Issuer hereunder shall automatically become immediately due and payable, without
presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived, anything contained herein to
the contrary notwithstanding. In addition to the foregoing remedies, upon the occurrence and during the continuance of any Event of Default,
Holder may exercise any other right, power or remedy granted to it by this Note or otherwise permitted to it by law, either by suit in
equity or by action at law, or both.
5.
Registration Rights.
(a)
Filing of a Registration Statement. Upon a written demand by Holder, Issuer shall prepare and file with the Securities and Exchange
Commission (“SEC”) a Registration Statement for the resale by the Holder of the Common Stock issuable upon the conversion
of the Note (and shares of Common Stock issuable upon the conversion of another note issued in connection with the Settlement Agreement)
as soon as practicable after the effective date of the Settlement Agreement and Release of All Claims. Notwithstanding the foregoing,
Issuer will have the right to delay the filing of such Registration Statement if the Issuer provides notice to Holder that it intends
to effect a registered public offering of its securities by April 30, 2024. In the event that Issuer gives notice to Holder that it intends
to conduct a registered public offering, Issuer shall have the right to delay the filing of a Registration Statement under this Section
5(a) until the lapse of any restrictive period prohibiting the filing of registration statements required under the public offering.
The Issuer shall use its best efforts to have such Registration Statement declared effective by the SEC as soon as practicable. The effectiveness
date of the Registration Statement under this Section 5(a) or (b) shall be deemed the Effective Registration Date; provided, however,
that if the Effective Registration Date shall not have occurred prior to 180 days from the issuance of this Note, the Effective Registration
Date as defined in this Note shall be deemed to occur on the 181st day after the issuance of this Note.
(b)
Piggyback Registration. If the Registration Statement provided for in subsection (a) above has not been filed and declared effective
by the SEC, and if Issuer determines on or after ninety (90) days from the issuance of this Note to prepare and file with the SEC a registration
statement or offering statement relating to an offering for its own account or the account of others under the Securities Act of 1933,
as amended (“Securities Act”), of any of its equity securities (other than on Form S-4 or Form S-8 (each as promulgated under
the Securities Act) or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of
any entity or business or equity securities issuable in connection with the Company’s stock option or other employee benefit plans),
then the Issuer shall deliver to the Holder a written notice of such determination and, if within fifteen (15) days after the date of
the delivery of such notice, such Holder shall so request in writing, the Issuer shall include in such registration statement or offering
statement all Common Stock that may be issued in connection with the conversion of this Note such Holder requests to be registered; provided,
however, the Company shall not be required to register any shares of Common Stock pursuant to this Section 5(b) that are eligible for
resale pursuant to Rule 144 without restriction (including, without limitation, volume restrictions) and without the need for current
public information required by Rule 144(c)(1) (or Rule 144(i)(2), if applicable) or that are the subject of a then-effective Registration
Statement.
(c)
Cutback. If an underwriter or placement agent that is to be engaged in an underwritten offering or best efforts offering advises
the Issuer in good faith that the dollar amount or number of Common Stock which the Holder desires to sell under this Section 5(a) or
(b), exceeds the maximum dollar amount or maximum number of shares that can be sold in such offering without adversely affecting the
proposed offering price, the timing, the distribution method, or the probability of success of such offering, then the Company, and its
underwriter or placement agent, will have to right to reduce the number of Common Stock requested to be registered by such Holder on
a pro rata basis.
(d)
Maintaining a Registration Statement. The Issuer shall maintain the effectiveness of any Registration Statement that has been
declared effective at all times, provided, however, that if the Issuer has received notification pursuant to Section 3(e) above that
the Holder has completed resales pursuant to the Registration Statement for all the shares of Common Stock, then the Issuer shall be
under no further obligation to maintain the effectiveness of the Registration Statement. Notwithstanding anything to the contrary contained
in this Note, the Issuer shall ensure that, when filed, each Registration Statement (including, without limitation, all amendments and
supplements thereto) and the prospectus (including, without limitation, all amendments and supplements thereto) used in connection with
such Registration Statement shall not contain any untrue statement of a material fact or omit to state a material fact required to be
stated therein, or necessary to make the statements therein (in the case of prospectuses, in the light of the circumstances in which
they were made) not misleading. The Issuer shall notify the Holder promptly if (i) the Registration Statement shall cease to be effective
under the Securities Act, (ii) the Common Stock shall cease to be authorized for listing on the NYSE American, (iii) the Common Stock
ceases to be registered under Section 12(b) or Section 12(g) of the Exchange Act or (iv) the Issuer fails to file in a timely manner
all reports and other documents required of it as a reporting company under the Exchange Act.
(e)
Completion of Resale Pursuant to the Registration Statement. After the Holder has completed the subsequent resale of the shares
of Common Stock pursuant to the Registration Statement, Holder will notify the Company in writing (which may be by e-mail) that all subsequent
resales are completed and the Company will be under no further obligation to maintain the effectiveness of the Registration Statement.
(d)
Filing Procedures. The Issuer shall (A) permit counsel to the Holder an opportunity to review and comment upon (i) each Registration
Statement at least three (3) Trading Days prior to its filing with the SEC and (ii) all amendments and supplements to each Registration
Statement (including, without limitation, the prospectus contained therein) (except for Annual Reports on Form 10-K, Quarterly Reports
on Form 10-Q, Current Reports on Form 8-K, and any similar or successor reports or prospectus supplements the contents of which is limited
to that set forth in such reports) within a reasonable number of days prior to their filing with the SEC, and (B) shall reasonably consider
any comments of the Holder and its counsel on any such Registration Statement or amendment or supplement thereto or to any prospectus
contained therein. The Issuer shall promptly furnish to the Holder, without charge, (i) electronic copies of any correspondence from
the SEC or the staff to the Issuer or its representatives relating to each Registration Statement (which correspondence shall be redacted
to exclude any material, non-public information regarding the Company or any of its subsidiaries), (ii) after the same is prepared and
filed with the SEC, one (1) electronic copy of each Registration Statement and any amendment(s) and supplement(s) thereto, including,
without limitation, financial statements and schedules, all documents incorporated therein by reference, if requested by the Holder,
and all exhibits and (iii) upon the effectiveness of each Registration Statement, one (1) electronic copy of the Prospectus included
in such Registration Statement and all amendments and supplements thereto; provided, however, the Company shall not be required to furnish
any document to the extent such document is available on EDGAR).
(e)
Amendments and Other Filings. The Issuer shall (i) prepare and file with the SEC such amendments (including post-effective amendments)
and supplements to a Registration Statement and the related prospectus used in connection with such Registration Statement, which prospectus
is to be filed pursuant to Rule 424 promulgated under the Securities Act, as may be necessary to keep such Registration Statement effective
at all times, and prepare and file with the SEC such additional Registration Statements in order to register for resale under the Securities
Act all of the Registrable Securities; (ii) cause the related prospectus to be amended or supplemented by any required prospectus supplement
(subject to the terms of this Note), and as so supplemented or amended to be filed pursuant to Rule 424 promulgated under the Securities
Act; (iii) provide the Holder copies of all correspondence from and to the SEC relating to a Registration Statement (provided that the
Company may excise any information contained therein which would constitute material non-public information, and (iv) comply with the
provisions of the Securities Act with respect to the Registration Statement. In the case of amendments and supplements to a Registration
Statement which are required to be filed pursuant to this Agreement (including pursuant to this Section 6.01(e) by reason of the Issuer’s
filing a report on Form 10-K, Form 10-Q, or Form 8-K or any analogous report under the Exchange Act, the Issuer shall file such report
in a prospectus supplement filed pursuant to Rule 424 promulgated under the Securities Act to incorporate such filing into the Registration
Statement, if applicable, or shall file such amendments or supplements with the SEC either on the day on which the Exchange Act report
is filed which created the requirement for the Issuer to amend or supplement the Registration Statement, if feasible, or otherwise promptly
thereafter.
6.
Representations and Warranties of the Issuer. The Issuer represents and warrants to the Holder that:
|
(a) |
Due Incorporation, Qualification.
The Issuer (i) is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware; (ii) has
the power and authority to own, lease and operate its properties and carry on its business as now conducted; and (iii) is duly qualified,
licensed to do business and in good standing as a foreign corporation in each jurisdiction where the failure to be so qualified or licensed
could reasonably be expected to have a material adverse effect on the Issuer. |
|
(b) |
Authority. The execution,
delivery and performance by the Issuer of the Note and the consummation of the transactions contemplated thereby (i) are within the power
of the Issuer and (ii) have been duly authorized by all necessary actions on the part of the Issuer. |
|
(c) |
Enforceability. Each Note executed,
or to be executed, by the Issuer has been, or will be, duly executed and delivered by the Issuer and constitutes, or will constitute,
a legal, valid and binding obligation of the Issuer, enforceable against the Issuer in accordance with its terms, except as limited by
bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors’ rights generally
and general principles of equity. |
|
(d) |
Non-Contravention. The execution
and delivery by the Issuer of the Note executed by the Issuer and the performance and consummation of the transactions contemplated thereby
do not and will not (i) violate the Charter or bylaws of the Issuer, or any material judgment, order, writ, decree, statute, rule or
regulation applicable to the Issuer; or (ii) result in the creation or imposition of any lien upon any property, asset or revenue of
the Issuer or the suspension, revocation, impairment, forfeiture, or nonrenewal of any material permit, license, authorization or approval
applicable to the Issuer, its business or operations, or any of its assets or properties. |
|
(e) |
Approvals. No consent, approval,
order or authorization of, or registration, declaration or filing with, any governmental authority or other person (including, without
limitation, the shareholders of any person) is required in connection with the execution and delivery of the Note by the Issuer and the
performance and consummation of the transactions contemplated thereby, other than such as have been obtained and remain in full force
and effect and other than such qualifications or filings under applicable securities laws as may be required in connection with the transactions
contemplated by this Note. |
|
(f) |
Shareholder Approval. In the event that
the aggregate number of shares of Common Stock that are convertible under this Note (and any other note issued to Holder under the Settlement
Agreement) would exceed the Exchange Cap, the Issuer shall cause a resolution seeking approval of the excess to be submitted for approval
of the stockholders at the next annual or special meeting, and any subsequent meeting until such approval is obtained. |
7.
Representations and Warranties of Holder. Holder represents and warrants to the Issuer upon the acquisition of the Note as follows:
|
(a) |
Binding Obligation. Holder has full legal capacity, power and authority to execute and deliver this Note and
to perform its obligations hereunder. This Note constitutes valid and binding obligations of Holder, enforceable in accordance with
its terms, except as limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement
of creditors’ rights generally and general principles of equity. |
|
|
|
|
(b) |
Securities Law Compliance. Holder has been advised that the Note and the underlying securities have not been registered
under the Act or any state securities laws and, therefore, cannot be resold unless it or they are registered under the Act and applicable
state securities laws or unless an exemption from such registration requirements is available. Investor is aware that the Issuer
is under no obligation to effect any such registration with respect to the Note or the underlying securities or to file for or comply
with any exemption from registration. Holder has not been formed solely for the purpose of making this investment and is purchasing
the Note for its own account for investment, not as a nominee or agent, and not with a view to, or for resale in connection with,
the distribution thereof, and Holder has no present intention of selling, granting any participation in, or otherwise distributing
the same. Holder has such knowledge and experience in financial and business matters that Holder is capable of evaluating the merits
and risks of such investment, is able to incur a complete loss of such investment without impairing Holder’s financial condition
and is able to bear the economic risk of such investment for an indefinite period of time. Investor is an “accredited investor”
as such term is defined in Rule 501 of Regulation D under the Act and shall submit to the Issuer such further assurances of such
status as may be reasonably requested by the Issuer. The residency of Holder (or, in the case of a partnership or corporation, such
entity’s principal place of business) is correctly set forth beneath Holder’s name on the signature page hereto. |
|
|
|
|
(c) |
Access to Information. Holder acknowledges that the Borrwer has given Holder access to the corporate records and accounts
of the Issuer and to all information in its possession relating to the Issuer, has made its officers and representatives available
for interview by Holder, and has furnished Holder with all documents and other information required for Holder to make an informed
decision with respect to the purchase of the Note. |
8.
Amendment and Waiver. Any provision of this Note may be amended, waived or modified only with the written consent of the Issuer
and the Holder provided however, that no such amendment, waiver or consent shall: (i) reduce the principal amount of any Note
without the Holder’s written consent, or (ii) reduce the rate of interest of any Note without the Holder’s written consent.
Any term of this Note may be amended and the observance of any term of this Note may be waived (either generally or in a particular instance
and either retroactively or prospectively), only with the written consent of the Issuer and Holder. Any amendment or waiver effected
in accordance with this paragraph shall be binding upon all of the parties hereto.
9.
Assignment by the Issuer. The rights, interests or obligations of the Issuer hereunder may not be assigned, by operation of law
or otherwise, in whole or in part, by the Issuer without the prior written consent of the Holder.
10.
Place of Payment. Payments of principal and interest and all notices and other communications to Holder hereunder or with respect
hereto are to be delivered to Holder such address as specified by Holder by prior written notice to the Issuer, including any transferee
of this Note.
11.
Costs of Collection. In the event that the Issuer fails to pay when due (including, without limitation upon acceleration in connection
with an Event of Default) the full amount of principal and/or interest hereunder, the Issuer shall indemnify and hold harmless Holder
of any portion of this Note from and against all costs and expenses incurred in connection with the enforcement of this provision or
collection of such principal and interest, including, without limitation, attorneys’ fees and expenses.
12.
Waivers. The Issuer hereby waives presentment, demand, notice, protest and all other demands and notices in connection with the
delivery, acceptance, performance, default or enforcement of this Note.
13.
Mutilated, Destroyed, Lost and Stolen Note. In case the Note shall be mutilated, lost, stolen or destroyed, the Issuer shall issue
a new Note of like date, tenor and denomination and deliver the same in exchange and substitution for and upon surrender and cancellation
of the mutilated Note, or in lieu of a lost, stolen or destroyed Note, upon receipt of evidence satisfactory to the Issuer of the loss,
theft or destruction of such Note.
14.
Interest Savings Clause. In the event any interest is paid on this Note which is deemed to be in excess of the then legal maximum
rate, then that portion of the interest payment representing an amount in excess of the then legal maximum rate shall be deemed a payment
of principal and applied against the principal of this Note.
15. Governing
Law. THIS NOTE AND THE RIGHTS AND DUTIES OF THE ISSUER AND HOLDER HEREOF SHALL BE GOVERNED BY, CONSTRUED IN AND ENFORCED IN
ACCORDANCE WITH, THE LAWS OF THE STATE OF DELAWARE TO CONTRACTS EXECUTED AND TO BE PERFORMED ENTIRELY WITHIN THAT STATE.
16.
Waiver of Jury Trial. The Issuer hereby agrees to waive their respective rights to a jury trial of any claim or cause of action
based upon or arising out of this Note.
17.
Jurisdiction. In the event of a dispute, Issuer and Holder agree to the jurisdiction set forth in the Settlement Agreement.
18.
Survival and Severability. The representations, warranties, covenants and agreements made herein shall survive the execution and
delivery of this Note. If any term, covenant or provision contained in this Note, or the application thereof to any Person or circumstance,
will be determined to be void, invalid, illegal or unenforceable to any extent or will otherwise operate to invalidate this Note, in
whole or part, then such term, covenant or provision only will be deemed not contained in this Note; the remainder of this Note will
remain operative and in full force and effect and will be enforced to the greatest extent permitted by law as if such clause or provision
had never been contained in it; and the application of such term, covenant or provision to other Persons or circumstances will not be
affected, impaired or restricted by that occurrence.
19.
Entire Agreement. This Note and the Settlement Agreement constitute, along with any exhibits hereto and thereto, and contain the
entire agreement among the Issuer and Holder and supersedes any and all prior agreements, negotiations, correspondence, understandings
and communications among the parties, whether written or oral, respecting the subject matter hereof.
20.
Notices. Any notice, request or other communication required or permitted hereunder will be in writing and be deemed to have been duly
given (a) when personally delivered or sent by email (the receipt of which is confirmed in writing); (b) one business day after being
sent by a nationally recognized overnight courier service; or (c) five business days after being sent by registered or certified mail,
return receipt requested, postage prepaid, to the parties at their respective addresses set forth below:
If
to the Issuer: Calidi Biotherapeutics, Inc.
Attn:
Wendy Pizarro, Esq.
4475
Executive Drive, Suite 200
San
Diego, CA 92121
wpizarro@calidibio.com
or contracts@calidibio.com
If
to the Holder: [__________]
[Remainder
of this page is intentionally blank]
IN
WITNESS WHEREOF, the Issuer has executed and delivered this Convertible Promissory Note on March 8, 2024
|
ISSUER: |
|
|
|
|
Calidi
Biotherapeutics, Inc. |
|
|
|
|
By: |
|
|
Name: |
Allan
Camaisa |
|
Title: |
Chief
Executive Officer |
Acknowledged
and Agreed: |
|
|
|
HOLDER: |
|
|
|
|
[__________] |
|
|
|
|
By: |
|
|
Name:
|
|
|
Title:
|
|
|
Exhibit
10.4
![](https://www.sec.gov/Archives/edgar/data/1855485/000149315224009678/ex10-4_001.jpg)
AMENDMENT
TO CONVERTIBLE NOTE
This
Amendment to the CONVERTIBLE NOTE in the principal amount of $1,500,000.00 (“Amendment”) is entered with an effective date
of March 11, 2024, by and between Calidi Biotherapeutics Inc., (the “Issuer”), and [_________] (the “Holder”),
collectively the “Parties” and each a “Party”.
WHEREAS,
the Issuer and Holder entered into the Convertible Note in the principal amount of $1,500,000.00 dated March 8, 2024 (the “Convertible
Note”), attached hereto as Exhibit A.
WHEREAS,
the Issuer and Holder desire to amend the terms of the Convertible Note as set forth below.
NOW
THEREFORE, in exchange for the mutual covenants set forth below, and other valuable consideration, the Parties agree to amend the Agreement
as follows:
The
following provision shall be deleted in its entirety in Section 1.(c): (iii) the Principal Amount shall be wired to Issuer’s bank
account.
The
terms of this Amendment shall be incorporated by reference into the Convertible Note. Besides the terms as forth herein, all of the terms,
conditions, and obligations of the Convertible Note shall remain in full force and effect.
IN
WITNESS WHEREOF, the Issuer and the Holder have caused this Convertible Note to be duly executed as of the date first written above.
|
ISSUER: |
|
CALIDI
BIOTHERAPEUTICS, INC. |
|
|
|
|
By: |
|
|
Name: |
Wendy
Pizarro, Esq. |
|
Title: |
Chief
Legal Officer |
HOLDER: |
|
|
|
[_________________] |
|
|
|
|
By: |
|
|
Name: |
|
|
Title: |
|
|
v3.24.0.1
Cover
|
Mar. 08, 2024 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Mar. 08, 2024
|
Entity File Number |
001-40789
|
Entity Registrant Name |
Calidi
Biotherapeutics, Inc.
|
Entity Central Index Key |
0001855485
|
Entity Tax Identification Number |
86-2967193
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
4475
Executive Dr.
|
Entity Address, Address Line Two |
Suite 200
|
Entity Address, City or Town |
San
Diego
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
92121
|
City Area Code |
(858)
|
Local Phone Number |
794-9600
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Common Stock Par Value 0. 0001 Per Share [Member] |
|
Title of 12(b) Security |
Common
stock, par value $0.0001 per share
|
Trading Symbol |
CLDI
|
Security Exchange Name |
NYSEAMER
|
Redeemable Warrants Each Whole Warrant Exercisable For One Share Of Common Stock At Exercise Price Of 11. 50 Per Share [Member] |
|
Title of 12(b) Security |
Redeemable
warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per share
|
Trading Symbol |
CLDIWS
|
Security Exchange Name |
NYSEAMER
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=CLDI_CommonStockParValue0.0001PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=CLDI_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
First Light Acquisition (AMEX:FLAG)
Historical Stock Chart
From Jul 2024 to Aug 2024
First Light Acquisition (AMEX:FLAG)
Historical Stock Chart
From Aug 2023 to Aug 2024